This company develops implantable cardioverter defibrillators (ICDs) designed to improve patient outcomes. Their focus is on creating a new generation of ICDs that enhance clinical results, lower therapy costs, and broaden access to this life-saving treatment.
Funding
Funding not disclosed
Founders
Product
Problem
Current implantable cardioverter defibrillators (ICDs) may have limitations in terms of patient outcomes, therapy costs, and accessibility, creating a need for improved devices. Existing ICD technology may not fully address the unmet needs in chronic disease management and therapy delivery.
Solution
North American EP Technology is developing a next-generation implantable cardioverter defibrillator (ICD) that leverages chronic sensing technology to improve patient outcomes and reduce the cost of care for multiple chronic conditions. Their sensing innovation adds a new dimension to remote monitoring of chronic diseases and guides therapy delivery. The company's proprietary, patented technical solution has been confirmed by successful preclinical studies. The new ICD aims to address long-standing unmet needs, improve clinical results, lower therapy costs, and broaden access to this life-saving treatment.
Target Audience
The primary target audience includes patients at risk of sudden cardiac arrest, electrophysiologists, cardiologists, and hospitals seeking to improve patient outcomes and reduce healthcare costs associated with ICD therapy.
Features
- Leading-edge chronic sensing technology for remote monitoring.
- Proprietary, patented technical solution.
- Substernal implantable ICD design.
- Strong and growing patent portfolio.
- Improved clinical outcomes.
- Reduced cost of care.
- Increased access to life-saving therapy.